Hybrid quantum-classical machine learning offers a path to leverage noisy intermediate-scale quantum (NISQ) devices for drug discovery, but optimal model architectures remain unclear. We systematically optimize the quantum-classical bridge architecture of generative adversarial networks (GANs) for molecule discovery using multi-objective Bayesian optimization. Our optimized model (BO-QGAN) significantly improves performance, achieving a 2.27-fold higher Drug Candidate Score (DCS) than prior quantum-hybrid benchmarks and 2.21-fold higher than the classical baseline, while reducing parameter count by more than 60%. Key findings favor layering multiple (3-4) shallow (4-8 qubit) quantum circuits sequentially, while classical architecture shows less sensitivity above a minimum capacity. This work provides the first empirically-grounded architectural guidelines for hybrid models, enabling more effective integration of current quantum computers into pharmaceutical research pipelines.
Hybrid quantum-classical machine learning offers a path to leverage noisy intermediate-scale quantum (NISQ) devices for drug discovery, but optimal model architectures remain unclear. We systematically optimize the quantum-classical bridge architecture of generative adversarial networks (GANs) for molecule discovery using multi-objective Bayesian optimization. Our optimized model (BO-QGAN) significantly improves performance, achieving a 2.27-fold higher Drug Candidate Score (DCS) than prior quantum-hybrid benchmarks and 2.21-fold higher than the classical baseline, while reducing parameter count by more than 60%. Key findings favor layering multiple (3-4) shallow (4-8 qubit) quantum circuits sequentially, while classical architecture shows less sensitivity above a minimum capacity. This work provides the first empirically-grounded architectural guidelines for hybrid models, enabling more effective integration of current quantum computers into pharmaceutical research pipelines.
The drug design process currently requires considerable time and resources to develop each new compound that enters the market. This work develops an application of hybrid quantum generative models based on the integration of parameterized quantum circuits into known molecular generative adversarial networks and proposes quantum cycle architectures that improve model performance and stability during training. Through extensive experimentation on benchmark drug design datasets, quantum machine 9 (QM9) and PubChemQC 9 (PC9), the introduced models are shown to outperform the previously achieved scores. Most prominently, the new scores indicate an increase of up to 30% in the quantitative estimation of druglikeness. The new hybrid quantum machine learning algorithms, as well as the achieved scores of pharmacokinetic properties, contribute to the development of fast and accurate drug discovery processes.
Abstract : We propose a hybrid quantum–classical framework that integrates variational quantum machine learning (QML) for molecular binding affinity prediction with quantum annealing for Pareto-optimal drug formulation design. Leveraging a four-qubit variational circuit, our QML model achieves superior predictive performance compared to state-of-the-art classical baselines, effectively capturing complex molecular interactions. In parallel, we formulate drug formulation optimization as a Quadratic Unconstrained Binary Optimization (QUBO) problem and solve it using D-Wave’s quantum annealer, enabling efficient identification of Pareto-optimal solutions that balance bioavailability, toxicity, and stability. By unifying predictive modeling and combinatorial optimization within a single pipeline, our framework demonstrates the potential of near-term quantum devices to accelerate and enhance critical stages of drug discovery. These findings underscore the transformative role of NISQ-era algorithms in bridging molecular informatics and formulation design, paving the way for scalable, data-driven pharmaceutical innovation.
Existing drug discovery pipelines take 5–10 years and cost billions of dollars. Computational approaches aim to sample from regions of the whole molecular and solid-state compounds called chemical space, which could be on the order of1060. Deep generative models can model the underlying probability distribution of both the physical structures and property of drugs and relate them nonlinearly. By exploiting patterns in massive datasets, these models can distill salient features that characterize the molecules. Generative adversarial networks (GANs) discover drug candidates by generating molecular structures that obey chemical and physical properties and show affinity toward binding with the receptor for a target disease. However, classical GANs cannot explore certain regions of the chemical space and suffer from training instabilities. The practical utility of such models is limited due to the vast size of the search space, characterized by millions of parameters. A full quantum GAN may require more than 90 qubits even to generate small molecules with up to nine heavy atoms. The proposed quantum GAN with a hybrid generator (QGAN-HG) model is composed of a hybrid quantum generator that supports various number of qubits and quantum circuit layers, and a classical discriminator. The QGAN-HG with less than 20% of the original parameters can learn molecular distributions as efficiently as its classical counterpart. Another extended version of the proposed QGAN-HG, which utilizes multiple quantum subcircuits, considerably accelerates our standard QGAN-HG training process and avoids the potential gradient vanishing issue of deep neural networks.
This study examines how quantum computing (QC) is being applied to molecular design and drug discovery. This study aims to investigates how QC surpasses classical limitations, focusing on empirical performance in precision, accuracy, and optimisation tasks. Study design use PRISMA 2009 guidelines, 15 empirical studies (2020-2025) were included. Data were extracted on the drug-discovery stage, the algorithm used, evaluation metrics, benefits, and limitations. The findings show QC outperforms classical methods particularly through hybrid quantum–classical models. Thirteen studies reported superior gains, including AUC–ROC values of 0.80–0.95, +30% improvement in drug-likeness (QED), +6% increase in prediction accuracy, and up to 99% accuracy in drug–target interaction tasks. However, noisy intermediate-scale quantum (NISQ) hardware limitations and poor scalability limit real-world deployment, due to noise, and limited qubit counts. Consequently, current performance results are largely simulation-based rather than hardware-validated. In contrast to prior algorithm-centric reviews, this study provides a consolidated empirical synthesis and proposes a hybrid quantum–classical pipeline that maps high-performing algorithms across the drug discovery workflow under NISQ-era constraints. These findings inform pharmaceutical research and development by identifying realistic adoption pathways and the boundaries of current technological readiness.
The convergence of Quantum Computing and Generative Artificial Intelligence (AI) marks a transformative leap in the field of drug discovery. Traditional drug development pipelines are often slow, costly, and limited by classical computational constraints. This paper presents a novel hybrid approach—QuantumGeneraDrug—that integrates quantum generative models with deep learning architectures to accelerate molecule generation, optimize binding affinities, and reduce computation time. A comprehensive literature survey highlights the evolution of both quantum algorithms and generative AI models applied to pharmaceutical research. The proposed system demonstrates improved performance over existing frameworks in key metrics such as valid molecule rate, druglikeness (QED) score, binding affinity accuracy, and processing time per compound. Comparative results are illustrated using numerical tables and visualized via bar and pie charts. The study concludes that Quantum Generative AI holds immense promise for next-generation drug discovery, especially in tackling complex diseases and enabling personalized medicine.
Hybrid Quantum Generative Adversarial Networks (HQ-GANs) have emerged as a promising class of models at the intersection of quantum computing and generative artificial intelligence. Unlike early quantum generative approaches that relied on fully quantum pipelines, hybrid QGANs combine parameterized quantum circuits with classical optimization and discrimination mechanisms, enabling practical training under the constraints of noisy intermediate-scale quantum (NISQ) hardware. This paper presents a comprehensive technical review of hybrid QGAN architectures, with a particular focus on implicit quantum representations and hybrid optimization strategies that enhance expressivity, stability, and scalability. We analyze how recent advances in variational circuit design, data re-encoding, Wasserstein-based objectives, and hybriddepth control have reshaped the feasibility of quantum generative learning. New mathematical formulations are introduced to describe implicit quantum mappings and hybrid adversarial convergence. Comparative analysis highlights performance trends, architectural trade-offs, and unresolved challenges related to noise, barren plateaus, and hardware–software mismatch. The paper concludes by outlining future research directions toward robust, application-ready quantum generative intelligence.